智飞生物：2025年上半年净利润亏损5.97亿元

Core Viewpoint - The company reported a significant decline in revenue and a net loss for the first half of 2025, attributed to decreased public willingness for vaccinations and changing market demands [1] Financial Performance - The company's revenue for the first half of 2025 was 4.919 billion yuan, representing a year-on-year decrease of 73.06% [1] - The net profit for the same period was a loss of 0.597 billion yuan, compared to a net profit of 2.234 billion yuan in the previous year [1] Market Dynamics - The decline in revenue and profit is influenced by multiple factors, including a decrease in public vaccination willingness and changes in market demand [1] - The company has adjusted its procurement and supply schedule for HPV vaccines in collaboration with Merck, and is actively conducting demand assessments to respond to market changes [1]